| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Clobetasol propionate 500 microgram/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing precisely clobetasol propionate 500 microgram/1 milliliter conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing precisely acetic acid 20 milligram/1 milliliter and hydrocortisone 10 milligram/1 milliliter conventional release ear solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| iseddikesyre + hydrocortison 2 % vægtvolumen/1 % vægtvolumen-opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| benzoylperoxid 50 mg + hydrocortison 5 mg lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| betamethasonacetat 3 mg/ml + betamethasondinatriumphosphat 3 mg/ml injektionsvæske, suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Betamethasone acetate + betamethasone sodium phospha 3mg/ns soluspan |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Betamethasone dipropionate + clotrimazole 0.64mg/10mg cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| betamethasondipropionat 0,5 mg + clotrimazol 10 mg lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| chloroxylenol 1 mg + hydrocortison 10 mg + pramoxinhydrochlorid 10 mg dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| clioquinol + hydrocortison + pramoxinhydrochlorid 3 % wt/wt/1 % wt/wt/0,5 % wt/wt |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| clioquinol 3 % wt/wt + hydrocortison 0,5 % wt/wt creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| clioquinol + hydrocortison 3 % wt/wt/0,5 % wt/wt lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Clioquinol + hydrocortisone 30mg/10mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| colistinsulfat + hydrocortisonacetat + neomycinsulfat 3 mg/10 mg/3,3 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethason 1 mg + neomycinsulfat 3,5 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethason 0,1 %wt/vol + tobramycin 0,3 %wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethason 1 mg + tobramycin 3 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Dexamethasone phosphate + dexamethasone sodium phospha 1mg/0ns solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat + lidocainhydrochlorid 4 mg/10 mg/ml injektionsvæske, opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Dexamethasone sodium phospha + neomycin sulfate 0ns/0ns solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat 1 mg +neomycinsulfat 3,5 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing precisely fluorometholone 1 milligram/1 milliliter and sulfacetamide sodium 100 milligram/1 milliliter conventional release eye suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| gentamicinsulfat 0,3 % wt/wt + prednisolonacetat 0,6 % wt/wt salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| gentamicinsulfat + prednisolonacetat 0,3 %/1 % vol/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hexachlorophen 5 mg + hydrocortison 5 mg + mentol 1,25 mg creme til topikal anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/1,6 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/10.000 opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison 10 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/7,5 mg/10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison 10 mg + neomycinsulfat 7,5 mg + polymyxin B-sulfat 1.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison + polymyxin B 5 mg/10.000 enheder dråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat + pramoxinhydrochlorid 1 % wt/vol/1 % wt/vol lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat + pramoxinhydrochlorid 1 % wt/wt/1 % wt/wt aerosol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Hydrocortisone acetate 10 mg/mL and pramocaine hydrochloride 10 mg/mL cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing precisely hydrocortisone acetate 25 milligram/1 milliliter and pramocaine hydrochloride 10 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat + pramoxinhydrochlorid 2,5 % wt/wt/1 % wt/wt lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat 2,5 % wt/wt + pramoxinhydrochlorid 1 % wt/wt salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| nystatin 100.000 enheder + triamcinolonacetonid 1 mg creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| nystatin 100.000 enheder + triamcinolonacetonid 1 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| nystatin 10.000 enheder + triamcinolonacetonid 1 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat + sulfacetamidnatrium 0,2 % wt/vol/10 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Prednisolone acetate 2 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat + sulfacetamidnatrium 0,25 % wt/vol/10 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Prednisolone acetate 2.5 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat 5 mg + sulfacetamidnatrium 100 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat 5 mg + sulfacetamidnatrium 100 mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonnatriumphosphat 2,5 mg + sulfacetamidnatrium 100 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing betamethasone and calcipotriol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat 24 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat 4 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat 10 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing precisely betamethasone (as betamethasone valerate) 1 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Clioquinol+flumethasone pivalate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing benzoyl peroxide and hydrocortisone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing ascorbic acid and clioquinol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| neomycinsulfat + polymyxin B-sulfat + prednisolonacetat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| colistinsulfat + hydrocortisonacetat + neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| chloroxylenol + hydrocortison + pramoxinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| ciprofloxacin 0,2 % + hydrocortison 1 % øreopløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat + neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| gentamicinsulfat + prednisolonacetat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Betamethasone dipropionate + clotrimazole |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethason + neomycinsulfat + polymyxin B-sulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| dexamethasonnatriumphosphat +neomycinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Product containing diiodohydroxyquinoline and hydrocortisone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| clioquinol + hydrocortison + pramoxinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Methylprednisolone sodium su 125mg/vial powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat 50 mg/ml injektionsvæske, suspension, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonnatriumsuccinat 1000 mg pulver til injektionsvæske, hætteglas a 8 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| betamethasondinatriumphosphat 3 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonnatriumphosphat 20 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonacetat 50 mg/ml injektionsvæske, suspension, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonnatriumsuccinat 500 mg pulver til injektionsvæske, hætteglas a 4 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| betamethasondinatriumphosphat 4 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonnatriumphosphat 20 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| triamcinolonhexacetonid 20 mg/ml injektionsvæske, suspension, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat 50 mg/ml injektionsvæske, suspension, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Dexamethasone isonicotinate 20 microgram and tramazoline hydrochloride 120 microgram/actuation nasal spray |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat 0,5 % wt/wt + sulfacetamidnatrium 10 % wt/wt salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortison 1 % + pramocain 1 % skumklysma |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Triamcinolone hexacetonide 5mg/mL injection suspension 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonnatriumphosphat 20 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| cortisonacetat 50 mg/ml injektionsvæske, suspension, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Tridesilon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonacetat 50 mg/ml injektionsvæske, suspension, hætteglas a 30 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonnatriumsuccinat 250 mg pulver til injektionsvæske, hætteglas, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| prednisolonnatriumphosphat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonnatriumphosphat 50 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| hydrocortisonnatriumsuccinat 100 mg pulver til injektionsvæske, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Prednisolone 20mg/100mL enema |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Budesonide refill 100dose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Budesonide refill 200dose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Triamcinolone 40mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
| Triamcinolone 80mg/2mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
binyrehormonmiddel |
Inferred relationship |
Some |
|
FHIR